As reported by Fierce Pharma, AstraZeneca is joining forces with Amgen to promote their bone drug denosumab in the Japanese market. The deal also involves Daiichii Sankyo who currently hold Japanese rights to the drug.
This is a great opportunity for AstraZeneca to further boost their presence in the Japanese market. Japan is currently the pharmaceutical company’s second largest market and EVP Tony Zook believes the deal will further strengthen their presence, “Collaborations like this are a key part of our strategy to bring innovative medicines to patients. “This partnership leverages our long-standing commitment to oncology in Japan.”
It’s great news for Amgen also – further strengthening the marketing effort and exposure of their drug which is also being marketed across Europe and a number of emerging markets by GlaxoSmithKline.